iShares US Pharma

Elanco EVP Rajeev A. Modi Buys Nearly 5,000 Shares, Total Holdings Rise to Approx 160k

Elanco CEO Jeffrey N. Simmons Buys 4,971 Shares and Receives 142 DSUs

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UBS Upgrades Jazz Pharma to Buy, Raises Price Target to $307

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

FactSet Survey: Analysts Cut ZTS Median Price Target to $117

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Elanco Launches New Anti-IL-31 Monoclonal Antibody Befrena for Canine Allergic Dermatitis

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

MGRX

ARKG

SBIO

LABU

Mangoceuticals, Inc. reported Q1 2026 revenue of $67.9K, down 37.9% from $109.3K in Q1 2025, with a net loss of $3.7M and a diluted EPS of $(0.22). The decline is attributed to a focus on in-house website development and TRT testing. The company is shifting to third-party fulfillment and plans to commercialize new products, including Dermytol in Q3 2026, while implementing cost controls.

TradingView

Mangoceuticals

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares Biotechnology ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

ELAN

Rajeev A. Modi, EVP of Elanco, acquired 4,911 shares at $20.35, totaling $99,923.85. His direct stock holdings increased to 160,812 shares. Additionally, he gained 74 deferred stock units priced at $19.86, raising his total to 9,339 units.

PUBT

Elanco Animal Health

Elanco EVP Rajeev Modi acquires 4,911 common shares worth $99,923.85

Pfizer Inc. (PFE) shares rose 1.30% to $25.66 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Eli Lilly. Despite the gain, Pfizer remains 10.73% below its 52-week high of $28.75. The trading volume reached 40.9 million, surpassing its 50-day average of 37.8 million.

- Shares of Pfizer Inc. (PFE) increased by 1.30% to $25.66 amid a generally negative trading day for the stock market.  
- The stock remains 10.73% below its 52-week high of $28.75, reached on April 2nd, while competitors like Johnson & Johnson and Eli Lilly saw gains.  
- Trading volume for Pfizer was 40.9 million, surpassing its 50-day average of 37.8 million.

MarketWatch Automated

Pfizer

Invesco Nasdaq Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Eli Lilly

Abbott Laboratories

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

IMRX

Chardan Capital analyst Geulah Livshits has reiterated a Buy rating on Immuneering (IMRX) with a price target of $20.00. Livshits, who focuses on the Healthcare sector, has an average return of 7.8% and a 35.98% success rate on recommended stocks. Mizuho Securities also maintained a Buy rating on the stock, setting a price target of $12.00.

Tip Ranks

Immuneering

Palvella Therapeutics

Iovance Biotherapeautics

Tenaya Therapeutics

Mizuho Financial

Mizuho Financial Group, Inc.

Immuneering (IMRX) Gets a Buy from Chardan Capital

AMGN

Amgen Inc. (AMGN) shares rose 1.96% to $330.75 on a weak trading day for the market, breaking a three-day losing streak. Despite this gain, the stock remains 15.47% below its 52-week high of $391.29. Competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, with trading volume surpassing its 50-day average.

Amgen

Abbvie

Factset Research

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

Regencell Bioscience has announced a registered direct offering of 985,222 ordinary shares priced at $20.30 each, aiming for gross proceeds of approximately $20 million. The offering is led by a $19 million investment from a new institutional investor, with closing expected around May 20, 2026, subject to customary conditions. Univest Securities is the sole placement agent.

Regencell Bioscience

Univest Financial

Regencell Bioscience prices 985,222-share registered direct offering at $20.30 each

ABBV

AbbVie Inc. (ABBV) shares rose 2.08% to $213.76 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Pfizer. The stock ended 12.68% below its 52-week high of $244.81. Trading volume reached 7.1 million, surpassing the 50-day average of 6.9 million.

AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

BBIO

BridgeBio Pharma President and CFO Thomas Trimarchi sold 13,651 shares between May 16-18 for USD 64.82 to USD 65.95 each, totaling USD 2.41 million. He withheld 22,781 shares at USD 66.13 to cover taxes related to RSU vesting, retaining 359,194 shares post-transactions.

Bridgebio Pharma

BridgeBio Pharma President, CFO Thomas Trimarchi disposes of USD 2.41 million shares

ETON

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights to the leishmaniasis drug IMPAVIDO (miltefosine) through a supply and distribution agreement with a Knight Therapeutics affiliate. The rights will take effect on September 26, 2026, contributing to Eton's rare disease portfolio and marking another product launch planned for that year. IMPAVIDO is the only FDA-approved oral treatment for certain forms of leishmaniasis.

Eton Pharmaceuticals

Eton Pharmaceuticals secures US commercialization rights to leishmaniasis drug Impavido

RYTM

Rhythm Pharmaceuticals' CAO Christopher Paul German sold 4,643 shares for $428,131.03 on May 15, 2026, reducing his holdings to zero. The shares were sold at $92.21 each, following option exercises for 4,442 shares at strike prices between $17.97 and $56.69.

Rhythm Pharma

Rhythm Pharma Controller, CAO Christopher Paul German disposes 4,643 shares worth $428,131.03

WGRX

Wellgistics Health, Inc. reported Q1 2026 revenue of $1.56M, down 85.6% from $10.86M a year ago, with a net loss of $7.74M, an improvement from a $32.43M loss in the previous year. The decline in revenue was attributed to reduced distribution activity and liquidity issues, while pharmacy retail sales increased. The company completed acquisitions to enhance its healthcare ecosystem and is investing in sales and marketing to boost brand awareness and customer acquisition.

Wellgistics Health

SPDR Pharmac

VanEck Pharmaceutical ETF

Invesco Pharmaceuticals ETF

Wellgistics Health, Inc. 1Q 2026: Revenue $1.56M, EPS ($0.07) — 10-Q Summary

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

iShares US Pharma(IHE.US)

MANGOCEUTICALS, INC. 1Q 2026: Revenue $67.9K, EPS $(0.22) — 10-Q Summary

Elanco EVP Rajeev Modi acquires 4,911 common shares worth $99,923.85

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

Immuneering (IMRX) Gets a Buy from Chardan Capital

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day